EXPLORING NEW MEDICAL HORIZONS
It took a long time – far too long, but better late than never – for U.S. regulators to catch up with science in the area of behavioral medicine. That’s not unusual because governments tend to be inefficient, but the Food and Drug Administration couldn’t deny what’s been proven by rigorous scientific research.
For patients who suffer from chronic depression, anxiety, and other mood disorders, the medications they get from their doctors often fail to effectively treat the symptoms. In other cases, they’re dangerously addictive. Sometimes, they could have unmanageable side effects or can drastically change the patient’s personality or behavior.
Instead of having to deal with all of that, imagine having access to a treatment that’s quicker and potentially more effective without so many unwanted side effects. This is a reality, and it’s happening today thanks to scientific breakthroughs by a small but growing community of researchers.
In recent years, clinics have experimented with the intravenous delivery of ketamine, a psychedelic agent that’s currently being researched for its ability to treat a range of mental health conditions including depression, anxiety, and post-traumatic stress disorder (PTSD).
Ketamine got a bad rap years ago because it had been used illegally as a so-called “party drug,” but it recently earned legitimacy in March of 2019 when the Food and Drug Administration approved a nasal-spray version of ketamine. This was a landmark decision and a godsend to the estimated five million Americans who suffer from depression that hasn’t responded to other treatments.
The research findings are already highly encouraging, with ketamine found to treat depression faster than traditional antidepressants. And while Prozac typically takes weeks or months before suicidal patients can manage their urge to self-harm, ketamine was found to quell potentially suicidal thoughts within 24 to 48 hours.
This is great news for the millions of people around the world who suffer from depression and other mood disorders, but the cycle wouldn’t be complete unless a company could step up and deliver safe, effective ketamine products to the public quickly and reliably.
The company at the forefront of this scientific movement to deliver better behavioral health treatments is Champignon Brands (CSE: SHRM, OTC: SHRMF), a emerging leader in providing novel solutions through the development and commercialization of rapid-onset, psychedelic-based treatments.
Champignon’s flagship clinic is licensed to administer ketamine treatments for indications, including, but not limited to, depression, bipolar disorder, posttraumatic stress disorder and obsessive-compulsive disorder (OCD). The company’s clinic is the only vertically integrated rapid-onset treatment centre operating from proof of concept to human clinical trials and publication, with study results in peer-reviewed journals by the world’s leading experts in psychopharmacology.
The company stands ready to, among other things, open a minimum of five new clinics in key markets, including New York, Florida and California, which are anticipated to be fully operational by Q4 2020.
With regulators relaxing their rules and Champignon making great strides in developing the market, there’s no limit to how far ketamine-enhanced therapies could go in treating behavioral issues better, faster, and less problematically than any traditional medication ever has.
RECOMMENDATION: MAKE Champignon Brands (CSE: SHRM, OTC: SHRMF) A CORE STOCK IN YOUR PORTFOLIO.
Consider becoming a shareholder of Champignon Brands (CSE: SHRM, OTC: SHRMF)!
For further updates on Champignon Brands, subscribe now!
We are not brokers, investment or financial advisers, and you should not rely on the information herein as investment advice. We are a marketing company. If you are seeking personal investment advice, please contact a qualified and registered broker, investment adviser or financial adviser. You should not make any investment decisions based on our communications. You should know that we have been compensated three hundred thousand dollars, directly by the company, for a two year public awareness campaign. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT recommendations. The securities issued by the companies we profile should be considered high risk and, if you do invest, you may lose your entire investment. Please do your own research before investing, including reading the companies’ SEC filings, press releases, and risk disclosures. Information contained in this profile was provided by the company, extracted from SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.
Please read our full disclaimer at PortfolioWealthGlobal.com/